伦敦/纽约 - 生物技术公司 Compass Pathways plc (NASDAQ:CMPS) 周二宣布拟进行1.5亿美元的美国存托股份 (ADS)公开发行,并计划授予承销商最多额外购买2,250万美元ADS的选择权。该公司目前交易价格为$7.62,市值约为7.38亿美元,根据 InvestingPro 分析,估值略显偏高。

Investing.com - RBC Capital将 Compass Pathways (NASDAQ:CMPS) 的目标价从21美元上调至22美元,同时维持跑赢大盘评级。根据 InvestingPro 数据,该股目前交易价格为7.63美元,波动性显著,过去一周飙升20.92%。

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

In two large-scale trials, Compass Pathways' proprietary form of psilocybin improved people's depression symptoms better than controls.

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the launch of a proposed public offering of $150.0 ...

Compass Pathways (CMPS) stock jumps as the company says psychedelic drug COMP360 hit late-stage trial endpoint in ...

Today, Compass updated investors on its drug trial progress, and the stock shot higher. Compass announced two Phase 3 trials ...

Feb 17 (Reuters) - Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy reduced the severity of symptoms in a late-stage study, sending its shares up nearly 23%. The ...